title: Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+ cells.
abstract: BACKGROUND
  Allogeneic peripheral blood stem cell (PBSC) transplantation is widely performed as a curative therapy for hematopoietic malignancies. Donors for PBSC harvest (PBSCH) are usually healthy subjects and undergo granulocyte-colony-stimulating factor treatment and apheresis procedures. A considerable proportion of donors experience poor mobilization, necessitating additional harvesting or marrow collection or remobilization. Although some characteristics have been reported to correlate with poor mobilization, they may not be taken into account in selecting PBSC donors. To protect healthy donors, it is preferable to predict the number of apheresis procedures needed for PBSCH before the procedure is initiated.
  
  
  METHODS
  A retrospective cohort study of 83 subjects was conducted, using statistical models to predict the probability of obtaining a sufficient number of CD34+ cells (>or=2.0 x 10(6)/kg) in the first to the third apheresis procedures and the probability of failure to obtain sufficient cells within three apheresis sessions. This study explored potential candidate factors in an ordinal probit regression analysis.
  
  
  RESULTS
  Significant factors predicting successful PBSCH were donor age, donor sex, and body weight difference between donor and recipient. The predictive model showed good agreement with the observed number of apheresis sessions. Simulation tables are presented with this model.
  
  
  CONCLUSIONS
  The statistical model developed to predict the number of apheresis procedures for PBSCH may be useful for planning PBSCH in clinical practice.
authors.affiliation: Department of Transfusion Medicine, Okayama University Hospital, Okayama, Japan. namban@md.okayama-u.ac.jp
authors.forename: Noriko
authors.initials: N
authors.lastname: Namba
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Shiro
authors.initials: S
authors.lastname: Kubonishi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Maeda
authors.forename: Masami
authors.initials: M
authors.lastname: Niiya
authors.forename: Katsuji
authors.initials: K
authors.lastname: Shinagawa
authors.forename: Norio
authors.initials: N
authors.lastname: Koide
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism*; D001781:Blood Component Removal / Q000379:methods*; D001782:Blood Donors / Q000706:statistics & numerical data*; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor